PDCD1 and non-small cell lung carcinoma: In the CONTACT-01 study (phase III, NCT04471428), atezolizumab combined with cabozantinib versus docetaxel is evaluated in patients with metastatic NSCLC previously treated with an anti-PD-L1/PD-1 and platinum-containing chemotherapy.